NCT02558348: An overdue trial by Advenchen Laboratories, LLC
This trial is overdue. It was due to report 7 years, 1 month ago.
Think we've made a mistake? Before contacting us, review the criteria in our paper. In particular, bear in mind the following:
- We can only rely on the structured data that sponsors put into the registry: they may enter incorrect or incomplete data.
- Reporting in a journal is not enough. The FDAAA rules state that the trial must be reported on ClinicalTrials.gov.
- Terminated trials are required to report results. Only withdrawn trials (which never recruited a single patient) are not.
Full data
| Full entry on ClinicalTrials.gov | NCT02558348 |
|---|---|
| Title | A Phase 1/2a Evaluation of the Safety, Pharmacokinetics and Efficacy of AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) |
| Results Status | Overdue |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Nov. 30, 2015 |
| Completion date | Feb. 14, 2017 |
| Required reporting date | Feb. 14, 2018, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | April 2, 2025 |
| Days late | 2604 |